Profile data is unavailable for this security.
About the company
Cenra Inc is a Taiwan-based company mainly engaged in the provision of general investment related businesses. Through its subsidiary, the Company conducts the development, manufacturing and sales of pharmaceuticals, agricultural and livestock drugs, personal hygiene and health products and the import and sale of medical instruments. Its subsidiaries’ products are pharmaceuticals and health products, including human medicines, such as prescription and indicated drugs, over-the-counter medicines, and disease treatment products; medical equipment, such as blood pressure monitors, blood glucose meters, and artificial joints; animal medicines, supplementary feeds, and feed additives, providing animal treatment, disease prevention, and nutritional supplement products; daily necessities, such as toothpaste, tooth powder, mouthwash and other oral hygiene and health products, hand cleansers, dry hand sanitizers, shower gels, medicated soaps and other lotion products, skin care series and other.
- Revenue in TWD (TTM)8.94bn
- Net income in TWD371.76m
- Incorporated2024
- Employees1.40k
- LocationCenra IncTAIPEI 100TaiwanTWN
- Phone+886 223124200
- Fax+886 223615143
- Websitehttps://www.cenra.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phytohealth Corp | 163.13m | -86.82m | 3.22bn | 84.00 | -- | 1.67 | -- | 19.72 | -0.4371 | -0.4371 | 0.8213 | 9.72 | 0.0679 | 0.6269 | 4.19 | -- | -5.15 | -5.66 | -6.35 | -7.31 | 39.92 | 47.70 | -75.82 | -92.91 | 31.96 | -- | 0.0088 | -- | 19.95 | 8.62 | 40.67 | -- | -40.76 | -- |
| Nang Kuang Pharmaceutical Co Ltd | 2.14bn | 122.15m | 4.36bn | 552.00 | 35.75 | 1.87 | 14.34 | 2.04 | 1.21 | 1.21 | 21.15 | 23.09 | 0.5788 | 2.08 | 7.71 | -- | 3.31 | 6.75 | 4.92 | 9.64 | 33.24 | 34.77 | 5.72 | 12.22 | 0.6684 | 14.94 | 0.1795 | 82.74 | 10.81 | 6.92 | -43.63 | 14.41 | 19.51 | 10.76 |
| Sinphar Pharmaceutical Co Ltd | 3.04bn | 332.79m | 5.63bn | 984.00 | 16.95 | 1.77 | 9.84 | 1.85 | 1.83 | 1.83 | 16.78 | 17.56 | 0.4901 | 2.34 | 6.85 | -- | 5.29 | -0.0147 | 6.91 | -0.0203 | 38.51 | 37.49 | 10.80 | -0.0344 | 1.58 | 19.25 | 0.3435 | 79.70 | 3.72 | 5.98 | 67.01 | 111.88 | 3.31 | 60.95 |
| Cenra Inc | 8.94bn | 371.76m | 5.66bn | 1.40k | 25.41 | 0.756 | 7.83 | 0.6338 | 1.50 | 1.50 | 34.28 | 50.26 | 0.7106 | 2.15 | 5.73 | -- | 2.97 | 3.69 | 4.29 | 4.96 | 37.10 | 36.56 | 4.18 | 5.50 | 0.7054 | -- | 0.2976 | 52.77 | 1.40 | 2.50 | -32.51 | -2.72 | 3.57 | -8.97 |
| Formosa Pharmaceuticals Inc | 137.46m | -200.59m | 5.87bn | -- | -- | 3.66 | -- | 42.72 | -1.49 | -1.49 | 1.02 | 10.62 | -- | -- | -- | -- | -- | -40.34 | -- | -44.21 | 84.63 | -- | -145.95 | -2,488.28 | -- | -- | 0.0167 | -- | 2,270.49 | -- | 20.75 | -- | -42.98 | -- |
| Panion & BF Biotech Inc | 2.04bn | 121.33m | 7.66bn | 321.00 | 63.14 | 4.07 | 26.30 | 3.76 | 1.41 | 1.41 | 23.73 | 21.94 | 0.6546 | 1.72 | 9.66 | -- | 3.90 | 4.08 | 5.72 | 5.63 | 52.43 | 52.37 | 5.96 | 5.93 | 0.8804 | 16.87 | 0.2717 | 111.06 | -21.54 | 5.96 | -57.65 | -13.47 | 35.39 | -3.23 |
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 2.90m | 1.95% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 2.62m | 1.76% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 2.42m | 1.62% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 1.14m | 0.76% |
| American Century Investment Management, Inc.as of 07 Nov 2024 | 181.00k | 0.12% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 135.48k | 0.09% |
| DFA Australia Ltd.as of 30 Sep 2024 | 73.46k | 0.05% |
| Vanguard Global Advisers LLCas of 30 Sep 2024 | 33.50k | 0.02% |
| Vanguard Fiduciary Trust Co.as of 31 Aug 2024 | 0.00 | 0.00% |
| LGT Capital Partners AG (Investment Management)as of 31 May 2024 | 0.00 | 0.00% |
